pyrroles has been researched along with Libman-Sacks Disease in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (6.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (36.67) | 29.6817 |
| 2010's | 17 (56.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Altamirano-Lagos, MJ; Fernández-Fierro, A; Funes, SC; Gómez-Santander, F; Jara, EL; Kalergis, AM; Mackern-Oberti, JP; Pulgar-Sepúlveda, R; Rebolledo-Zelada, D; Ríos, M; Rivera-Perez, D; Roa, JC; Villarroel, A | 1 |
| Abdel, MP; Brause, B; Chen, AF; Dasa, V; George, M; Gewurz-Singer, O; Giles, JT; Gililland, J; Goodman, M; Goodman, SM; Guyatt, G; Hurley-Rosenblatt, A; Johnson, B; Kirou, K; Lee, S; Losina, E; MacKenzie, R; Mandl, LA; Michaud, K; Mikuls, T; Miller, AS; Mont, MA; Russell, L; Sah, A; Sculco, P; Singh, JA; Sporer, S; Springer, B; Stryker, L; Turgunbaev, M; Yates, A | 2 |
| Li, H; Li, M; Tian, X; Wang, Q; You, H; Zeng, X; Zhang, G; Zhang, S; Zhao, J | 1 |
| Ardoin, SP; Barnhart, HX; Bowyer, SL; Brunner, HI; Eberhard, A; Evans, GW; Higgins, GC; Ilowite, NT; Imundo, LF; Jung, L; Kimura, Y; Klein-Gitelman, M; Levy, D; McCurdy, DK; Mieszkalski, KL; Punaro, L; Reed, AM; Sandborg, CI; Schanberg, LE; Sherry, DD; Silver, RM; Silverman, E; Singer, NG; Soep, JB; Thompson, SD; von Scheven, E; Wagner-Weiner, L; Wallace, C; Yow, E | 1 |
| Farajzadegan, Z; Fatemi, A; Kazemi, M; Moosavi, M; Sayedbonakdar, Z; Smiley, A | 1 |
| Chikazawa, M; Hagihara, Y; Hioki, Y; Maruyama, S; Matsumi, N; Miyashita, H; Nakashima, F; Otaki, N; Shibata, T; Shimozu, Y; Uchida, K | 1 |
| Abdalrahman, Z; Blanco, L; Brooks, SR; Furumoto, Y; Gadina, M; Hoffmann, V; Kaplan, MJ; Mast, L; Nunez, L; O'Shea, JJ; Remaley, AT; Sciumè, G; Smith, CK; Thacker, SG; Trier, AM; Tsai, WL; Zhao, W | 1 |
| Graham, KL; Higgins, JP; Ho, PP; Lee, LY; Steinman, L; Utz, PJ | 1 |
| Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W | 1 |
| Ferreira, GA; Sato, EI; Teixeira, AL | 1 |
| Christopher-Stine, L; Kiani, AN; Magder, LS; Petri, MA; Post, W | 1 |
| Dziedzic, H; Gryga, K; Konieczynska, M; Musial, J; Plazak, W; Podolec, P; Tomkiewicz-Pajak, L | 1 |
| Kiani, AN; Magder, LS; Petri, M; Post, WS | 1 |
| Gabriel, CL; Kastelein, JJ; Major, AS; Mendez-Fernandez, YV; Stroes, ES; Tak, PP; van Leuven, SI; Wade, NS; Wilhelm, AJ | 1 |
| Ravelli, A | 1 |
| Ardoin, SP; Barnhart, HX; Bowyer, SL; Brunner, HI; Eberhard, A; Evans, GW; Higgins, GC; Ilowite, NT; Imundo, LF; Jung, L; Kimura, Y; Klein-Gitelman, M; McCurdy, D; Mieszkalski, KL; Provenzale, J; Punaro, M; Reed, AM; Sandborg, C; Schanberg, LE; Sherry, DD; Silver, R; Silverman, E; Singer, NG; Soep, JB; Thompson, SD; von Scheven, E; Wagner-Weiner, L; Wallace, C; Yow, E | 1 |
| Chyou, S; Ekland, EH; Lu, TT; Tian, S | 1 |
| Steichen, O | 1 |
| Erhart, KH; Graziadei, IW; Obermoser, GE; Sepp, NT; Vogel, W | 1 |
| Abud-Mendoza, C; Baranda, L; Cruz-Rizo, J; Cuevas-Orta, E; de la Fuente, H; González-Amaro, R | 1 |
| Belmont, HM; Lydon, E | 1 |
| Cairns, T; Cook, HT; Elliot, V | 1 |
| Ehrenstein, MR; Isenberg, DA; Jury, EC; Mauri, C | 1 |
| Andrade, LE; Ferreira, GA; Navarro, TP; Sato, EI; Telles, RW | 1 |
| Bielinska, A; Gluszko, P | 1 |
| Kotyla, PJ | 1 |
| Claypool, RG; Copley, JB; Wellborne, FR | 1 |
| Barth, WF; Ruppert, GB | 1 |
| Hidalgo, C; Jaimez, L; Jiménez-Alonso, J; Leon, L; Sabio, JM | 1 |
2 review(s) available for pyrroles and Libman-Sacks Disease
| Article | Year |
|---|---|
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Psoriatic; Arthritis, Rheumatoid; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Elective Surgical Procedures; Glucocorticoids; Humans; Lupus Erythematosus, Systemic; Perioperative Care; Piperidines; Pyrimidines; Pyrroles; Rheumatic Diseases; Rheumatology; Spondylarthritis; Spondylitis, Ankylosing; Surgeons; United States | 2017 |
[Statins--are they potentially useful in rheumatology?].
Topics: Arthritis, Rheumatoid; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Osteoporosis; Pyrroles; Rheumatic Diseases; Simvastatin; Treatment Outcome | 2007 |
10 trial(s) available for pyrroles and Libman-Sacks Disease
| Article | Year |
|---|---|
Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.
Topics: Adolescent; Age Factors; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Arteries; Carotid Intima-Media Thickness; Cholesterol, LDL; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Prospective Studies; Puberty; Pyrroles; Treatment Outcome | 2014 |
Atorvastatin effect on systemic lupus erythematosus disease activity: a double-blind randomized clinical trial.
Topics: Adult; Antirheumatic Agents; Atorvastatin; Blood Sedimentation; C-Reactive Protein; Double-Blind Method; Female; Heptanoic Acids; Humans; Lipids; Lupus Erythematosus, Systemic; Male; Middle Aged; Pyrroles; Severity of Illness Index; Treatment Outcome | 2014 |
Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus.
Topics: Adult; Atorvastatin; Chemokine CXCL9; Chemokines; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferons; Lupus Erythematosus, Systemic; Pyrroles; Severity of Illness Index | 2010 |
Lupus Atherosclerosis Prevention Study (LAPS).
Topics: Adolescent; Adult; Aged; Atherosclerosis; Atorvastatin; Carotid Artery Diseases; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Middle Aged; Pyrroles; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography; Young Adult | 2011 |
Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study.
Topics: Adult; Aged; Atorvastatin; Calcinosis; Coronary Artery Disease; Coronary Vessels; Double-Blind Method; Female; Heart; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Middle Aged; Multimodal Imaging; Myocardial Perfusion Imaging; Myocardium; Positron-Emission Tomography; Prospective Studies; Pyrroles; Tomography, X-Ray Computed; Young Adult | 2011 |
Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Calcium; Carotid Artery Diseases; Carotid Intima-Media Thickness; Comorbidity; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Male; Maryland; Pyrroles | 2011 |
Use of atorvastatin in systemic lupus erythematosus in children and adolescents.
Topics: Adolescent; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Intima-Media Thickness; Child; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Lipids; Lupus Erythematosus, Systemic; Male; Pyrroles; Treatment Outcome; Young Adult | 2012 |
Therapy with statins in patients with refractory rheumatic diseases: a preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Atorvastatin; Biomarkers; Blood Sedimentation; C-Reactive Protein; Child; Chloroquine; Dose-Response Relationship, Drug; Granulomatosis with Polyangiitis; Heptanoic Acids; HLA-DR Antigens; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Lupus Erythematosus, Systemic; Middle Aged; Proteinuria; Pyrroles; Rheumatic Diseases; Rheumatic Fever; Simvastatin; Treatment Outcome | 2003 |
Avascular necrosis prevention with lipitor in lupus erythematosus.
Topics: Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Osteonecrosis; Pyrroles | 2005 |
Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial.
Topics: Adult; Atorvastatin; Brachial Artery; Coronary Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Pyrroles; Risk Factors; Severity of Illness Index; Ultrasonography; Vasodilation | 2007 |
18 other study(ies) available for pyrroles and Libman-Sacks Disease
| Article | Year |
|---|---|
Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice.
Topics: Animals; Antibodies, Antinuclear; Cell Differentiation; Cells, Cultured; Dendritic Cells; Dexamethasone; Disease Models, Animal; Humans; Immune Tolerance; Immunotherapy, Adoptive; Kidney; Lupus Erythematosus, Systemic; Lymphocyte Activation; Mice; Mice, Inbred MRL lpr; Pyrazines; Pyrroles; Rosiglitazone; T-Lymphocytes, Regulatory | 2019 |
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Psoriatic; Arthritis, Rheumatoid; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Biological Products; Glucocorticoids; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Orthopedics; Perioperative Care; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rheumatic Diseases; Rheumatology; Societies, Medical; Spondylitis, Ankylosing; United States | 2017 |
Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre.
Topics: Adolescent; Adult; Arthritis; Exanthema; Female; Humans; Lupus Erythematosus, Systemic; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2019 |
Lysine pyrrolation is a naturally-occurring covalent modification involved in the production of DNA mimic proteins.
Topics: Amino Acid Sequence; Animals; Benzothiazoles; Diamines; DNA; Ethidium; Female; Fluorescent Dyes; Humans; Immunoblotting; Lupus Erythematosus, Systemic; Lysine; Male; Mice, Inbred BALB C; Mice, Inbred MRL lpr; Models, Molecular; Molecular Sequence Data; Molecular Structure; Organic Chemicals; Protein Binding; Protein Processing, Post-Translational; Protein Structure, Tertiary; Proteins; Pyrroles; Quinolines; Spectrometry, Fluorescence | 2014 |
Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction.
Topics: Animals; Female; Lupus Erythematosus, Systemic; Mice; Mice, Inbred MRL lpr; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Vascular Diseases | 2017 |
Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus.
Topics: Administration, Oral; Animals; Antibodies, Antinuclear; Atorvastatin; Cell Proliferation; Cholesterol; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-4; Lupus Erythematosus, Systemic; Mice; Mice, Inbred NZB; Pyrroles; T-Lymphocytes; Treatment Outcome | 2008 |
Hydroxychloroquine-induced hyperpigmentation: the staining pattern.
Topics: Aged; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; Atorvastatin; Calcium Carbonate; Cardiomyopathy, Restrictive; Citalopram; Connective Tissue Diseases; Diuretics; Female; Furosemide; Glucosamine; Heptanoic Acids; Humans; Hydroxychloroquine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperpigmentation; Lupus Erythematosus, Systemic; Magnesium; Metolazone; Middle Aged; Naproxen; Omeprazole; Potassium Chloride; Prednisone; Pyrroles; Selective Serotonin Reuptake Inhibitors; Spironolactone | 2008 |
Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice.
Topics: Animals; Atherosclerosis; Atorvastatin; CD4-Positive T-Lymphocytes; Cholesterol; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mice; Mice, Inbred C57BL; Mycophenolic Acid; Pyrroles | 2012 |
Should children and adolescents with systemic lupus erythematosus be given statin therapy to prevent early atherosclerosis?
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Female; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Male; Pyrroles | 2012 |
Normalization of the lymph node T cell stromal microenvironment in lpr/lpr mice is associated with SU5416-induced reduction in autoantibodies.
Topics: Animals; Antibodies, Antinuclear; Autoantibodies; B-Lymphocytes; Cellular Microenvironment; Disease Models, Animal; Immunophenotyping; Indoles; Lupus Erythematosus, Systemic; Lymph Nodes; Mice; Mice, Inbred MRL lpr; Pyrroles; Receptors, Vascular Endothelial Growth Factor; T-Lymphocytes | 2012 |
A clinically relevant benefit of statins in young patients with systemic lupus erythematosus cannot be excluded: comment on the article by Schanberg et al.
Topics: Anticholesteremic Agents; Atherosclerosis; Female; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Male; Pyrroles | 2012 |
Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis.
Topics: Anticholesteremic Agents; Atorvastatin; Female; Hepatitis, Autoimmune; Heptanoic Acids; Humans; Immunosuppressive Agents; Liver; Liver Failure; Lupus Erythematosus, Systemic; Middle Aged; Pyrroles | 2003 |
Evolution of lesions over 10 years in a patient with SLE: flowchart approach to the new International Society of Nephrology (ISN)/Renal Pathology Society (RPS) classification of lupus nephritis.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Biopsy, Needle; Disease Progression; Follow-Up Studies; Hematuria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunoglobulin A; Immunoglobulin M; Immunosuppressive Agents; Kidney Glomerulus; Lupus Erythematosus, Systemic; Lupus Nephritis; Male; Organelles; Plasma Exchange; Pyrroles; Sclerosis; Severity of Illness Index; Software Design | 2006 |
Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Enzyme Activation; Female; G(M1) Ganglioside; Heptanoic Acids; Humans; Intracellular Fluid; Kinetics; Lupus Erythematosus, Systemic; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Male; Membrane Microdomains; Middle Aged; Protein Prenylation; Pyrroles; Receptors, Antigen, T-Cell; Signal Transduction; T-Lymphocyte Subsets | 2006 |
Comment on: Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 week controlled trial.
Topics: Atorvastatin; Controlled Clinical Trials as Topic; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Male; Pyrroles; Treatment Outcome; Vasodilation | 2008 |
Nephrotic range pseudoproteinuria in a tolmetin-treated patient.
Topics: False Positive Reactions; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged; Nephrotic Syndrome; Precipitin Tests; Proteinuria; Pyrroles; Tolmetin | 1983 |
Tolmetin-induced aseptic meningitis.
Topics: Adult; Female; Fever; Humans; Ibuprofen; Knee; Lupus Erythematosus, Systemic; Meningitis; Meningitis, Aseptic; Pain; Pyrroles; Tolmetin | 1981 |
Atorvastatin-induced reversible positive antinuclear antibodies.
Topics: Adult; Antibodies, Antinuclear; Atorvastatin; Autoimmune Diseases; Heptanoic Acids; Histones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Pyrroles | 2002 |